Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis

Inclusion Criteria: * Male or female volunteers, aged 18 years and above, with persistent asthma and allergic rhinitis * On a minimum of 200μg BDP of Inhaled corticosteroid (ICS) * FEV1 ≥ 60 % predicted * Positive skin prick test, or record of elevated allergen-specific IgE to at least 1 perennial allergen * Methacholine PC20 \< 8mg/ml at Visit 1 * Ability to give informed consent Exclusion Criteria: * Other respiratory diseases such as COPD, bronchiectasis or allergic bronchopulmonary aspergillosis (ABPA) which are considered to be significant in the opinion of the study physician Nasal polyps ≥ Grade 2 * An asthma exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 month of the study commencement, or 3 months if hospital admission was required * Any clinically significant medical condition that may endanger the health or safety of the participant. For example: Patients who have tuberculosis or any type of untreated infection or have had recent surgical operation or injury to the nose or mouth. * Participation in another trial within 30 days before the commencement of the study * Pregnancy or lactation * Unable to comply with the procedures of the protocol * Unable or unwilling to consent * Taking prohibited medications as listed in section 6.7.2 Prohibited Medications * Hypersensitivity to the active substances or to any of the excipients of Dymista Nasal Spray.